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INTRODUCTION
Lymphoma	 is	 one	 of	 the	 most	 common	
malignancies	 in	 dogs	 (Baba	 and	 Cătoi,	 2007).	
The	 annual	 rate	 of	 occurrence	 varies	 between	 6	
and	30	cases	per	100,000	dogs	(Vonderhaar	and	
Morrison,	 2002;	 Morrison,	 2004).	 Lymphoma	
accounts	 for	 approximately	7%	up	 to	24%	of	 all	
canine	neoplasms	and	about	83%	of	all	malignant	
haematopoietic	 tumors	 of	 this	 species	 (Valli	 et 
al.,	2017;	Vail	et al.,	2013).	Immunohistochemical	
examination	 is	 used	 to	 determine	 the	 type	
of	 tumoral	 cells,	 but	 this	 technique	 may	 also	
be	 useful	 for	 the	 determination	 of	 the	 initial	
diagnosis	 (Fournel-Fleury	et al.,	 1997;	Vail	et al.,	
1997;	Gibson	et al.,	2004;	Lana	et al.,	2006;	Gelain	
et al.,	2008;	Tasca	et al.,	2009;	Comazzi	and	Gelain,	
2011).	 The	 immunophenotype	 of	 a	 lymphocyte	
is	 identified	 by	 determining	 the	 expression	 of	
specific	molecules	for	B	lymphocytes	(e.g.,	CD79a,	
CD20,	CD21),	and	T	lymphocytes	(e.g.,	CD3)	(Ponce	
et al.,	2003;	Vail	et al.,	2013).	The	term	null	cell	is	
generally	used	for	lymphocytes	that	have	not	been	
immunoreactive	for	B	or	T	cells.	It	may	be	a	poorly	
differentiated	cell	of	unknown	origin,	or	it	may	be	
a	natural	killer	cell	(NK).	We	have	no	antibodies	or	
clear	definitions	to	recognize	NK-cell	 lymphomas	
in	animals,	as	there	is	in	human	medicine	(Ponce	
et al.,	2010;	Vezzali	et al.,	2010;	Valli	et al.,	2013).	
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ABSTRACT
Lymphomas	 occur	 by	 clonal	 expansion	 of	 lymphoid	 cells	 and	 have	 distinctive	 morphological	 and	
immunophenotypic	 features.	 Determination	 of	 canine	 lymphoma	 immunophenotype	 is	 useful	 for	 accurate	
prognosis	and	further	therapy.	In	the	suggested	study,	we	performed	an	immunohistochemical	evaluation	of	some	
cases	with	 canine	 lymphoma	diagnosed	 in	 the	Department	of	Pathology	 (Faculty	 of	Veterinary	Medicine,	 Cluj-
Napoca,	Romania),	 in	order	 to	 characterize	 them.	The	 investigation	 included	39	dogs	diagnosed	with	different	
anatomical	forms	of	lymphoma,	following	necropsy	analysis	or	assessment	of	biopsies.	The	diagnosis	of	lymphoma	
was	confirmed	by	necropsy	and	histopathology	(Hematoxylin-eosin	stain)	examinations.	The	collected	specimens	
were	analyzed	by	immunohistochemistry	technique	(automatic	method)	using	the	following	antibodies:	CD3,	CD20,	
CD21	and	CD79a.	The	analyzed	neoplasms	were	characterized	as	follows:	about	64.10%	of	cases	were	diagnosed	
as	B-cell	lymphomas,	33.34%	of	cases	as	T-cell	lymphomas,	whereas	2.56%	of	cases	were	null	cell	type	lymphomas	
(neither	B	nor	T).	Most	of	multicentric	(80%),	mediastinal	(60%)	and	primary	central	nervous	system	lymphomas	
(100%)	had	B	immunophenotype,	while	the	majority	of	cutaneous	(80%)	and	digestive	(100%)	lymphomas	had	
T	 immunophenotype.	 Immunohistochemical	 description	 of	 canine	 lymphomas	 can	 deliver	 some	major	 details	
concerning	their	behavior	and	malignancy.	Additionally,	vital	prognosis	and	efficacy	of	some	therapeutic	protocols	
are	relying	on	the	immunohistochemical	features	of	canine	lymphoma.
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Many	studies	have	confirmed	that	individuals	with	
CD3-immunoreactive	lymphoma	(i.e.,	T-type	cells)	
are	significantly	associated	with	shorter	remission	
and	survival	times	(Ruslander	et al.,	1996).
Considering	that,	in	Romania,	the	imunohisto-
chemical	 examination	 of	 canine	 lymphomas	
is	 rarely	 performed,	 we	 decided	 opportune	 to	
include	this	technique	in	our	study.
In	this	paper	we	performed	the	immunohisto-
chemical	characterization	of	some	canine	lympho-
ma	cases	diagnosed	in	the	Pathology	Department	
of	 Veterinary	 Medicine	 Faculty,	 Cluj-Napoca	
(Romania).	 Lymphomas	 were	 divided	 according	
to	 the	 immunophenotype	 into:	 B,	 T	 and	 null	
lymphomas.
MATERIALS AND METHODS
In	 this	 study	 were	 included	 39	 cases	 of	 va_
rious	 anatomical	 forms	 of	 canine	 lymphomas,	
diagnosed	in	the	Department	of	Pathology,	Faculty	
of	Veterinary	Medicine,	Cluj-Napoca.	The	diagnosis	
of	 lymphoma	 was	 established	 following	 the	
necropsy	and	histopathology	examination.	During	
the	necropsy,	 samples	were	 collected,	 embedded	
in	 paraffin	 and	 stained	 using	 Hematoxylin-eosin	
method.	 The	 immunohistochemical	 examination	
of	samples	was	carried	out	using	the	mouse	anti-
human	monoclonal	antibodies	 (Leica	Biosystems	
Newcastle	 Ltd,	 United	 Kingdom):	 CD3	 (clone	
LN10),	 CD20	 (clone	 MJ1),	 CD21	 (clone	 2G9),	
and	 CD79a	 (clone	 11E3).	 The	 samples	 were	
processed	 using	 the	 automatic	 Leica	 BondmaxTM 
Immunohistochemistry	system	(Leica	Biosystems	
Melbourne,	 Bond	Max	model,	M2	 12154	 series).	
Lastly,	the	obtained	samples	were	counterstained	
by	 Mayer’s	 hematoxylin.	 For	 all	 biomarkers	
applied,	the	tumoral	cells	that	had	the	cytoplasmic	
membrane	 marked	 in	 various	 levels	 of	 brown 
were	considered	positive.	
RESULTS AND DISCUSSION 
In	this	study	were	included	dogs	with	different	
anatomical	forms	of	lymphoma,	most	of	them	were	
multicentric,	 followed	by	mediastinal,	 cutaneous,	
digestive	 and	 primary	 central	 nervous	 system	
lymphoma.	 Immunohistochemical	 examination	
results	are	shown	in	Table	1.	
As can be seen in Figure 1, 64.1% (25 cases) of 
all lymphomas had B immunophenotype, 33.34% (13 
cases) were diagnosed with T-phenotype and 2.56% 
(1 case) were null phenotype (possibly natural killer 
lymphocytes - NK). No case of lymphoma with 
mixed phenotype has been identified. According 
to the literature, between 60% and 80% of canine 
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Tab.1.	Immunohistochemical	results	of	the	analyzed	lymphomas.
No. The type of  lymphoma Number of cases CD3 CD20 CD21 CD79a Immunophenotype
1. Multicentric	lymphoma 20 - + + + B
2. Multicentric	lymphoma 4 + - - - T
3. Multicentric	lymphoma 1 - - - - null
4. Mediastinal	lymphoma 3 - + + + B
5. Mediastinal	lymphoma 2 + - - - T
6. Cutaneous	lymphoma 4 + - - - T
7. Cutaneous	lymphoma 1 - + + + B
8. Digestive	lymphoma 3 + - - - T
9.
Primary	central	nervous	
system	lymphoma
1 - + + + B
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lymphomas have B-cell origin, 10% - 38% are T-cell 
lymphomas, about 22% have both B and T phenotype, 
while null phenotype lymphomas represent less than 
5% (Greenlee et al., 1990; Fournel-Fleury et al., 
2002; Wilkerson et al.,	2005).
Table	2	summarizes	the	results	of	the	immuno-
phenotype	 based	 on	 the	 anatomical	 distribution	
of	lymphomas	included	in	the	study.	In	the	case	of	
the	multicentric	form,	the	largest	proportion	was	
B-type	 lymphomas,	 respectively	 80%	 (20	 cases),	
followed	by	T	cell	lymphomas	16%	(4	cases)	and	
null	 type	 lymphomas	 4%	 (1	 case).	 It	 seems	 that	
other	 studies	 also	 show	 an	 incidence	 of	 about	
80%	of	the	B	phenotype	lymphomas	(Kiupel	et al.,	
1999).
In	Figure	2	(A,	B,	C	and	D)	we	can	observe	the	
immunolabelling	aspects	of	multicentric	lympho-
mas	with	the	tested	antibodies.
Cutaneous	T	 cell	 lymphoma	had	 a	 high	 inci-
dence,	 respectively	 80%	 (4	 cases),	 comparative	
with	cutaneous	B	cell	lymphoma	which	accounted	
for	20%	(1	case)	of	all	cutaneous	lymphomas.	Our	
results	partially	correspond	to	those	reported	by	
other	authors.
Although	cutaneous	lymphoma	is	a	heteroge-
neous	 neoplasm	 group	 including	 the	 mycosis 
fungoides	 epitheliotrophic	 form	and	 the	non-epi-
theliotrophic	form,	most	of	cutaneous	lymphomas	
show	 a	 T	 cells	 phenotype	 (Day,	 1995;	 Fry	 et 
al.,	 2003).	 Dogs	 with	 indolent	 T-cell	 cutaneous	
lymphoma	have	a	longer	survival	time	(Affolter	et 
al.,	2009).
In	Figure	3A	and	B,	it	can	be	seen	the	positive	
and	negative	 immunolabelling,	 in	a	case	of	T	cell	
cutaneous	lymphoma.	
Fig.1. Distribution	of	lymphomas	according	to	immunophenotype.
Tab. 2: Distribution	of	lymphoma	immunophenotype	depending	on	anatomical	form.
Anatomical	form
Multicentric Mediastinal Digestive Cutaneous
Central		
nervous	
systemImmunophenotype
B 80%	(20)* 60%	(3) 0% 20%	(1) 100%	(1)T 16%	(4) 40%	(2) 100%	(3) 80%	(4) -
null 4%	(1) - - - -
*(the	number	in	brackets	refers	to	the	number	of	cases)
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Fig. 2. Immunohistochemical	aspects	of	multicentric	lymphoma.
Multicentric	B-cell	lymphoma:	A,	B-	positive reaction	for	both	CD20	and	CD21	antibodies;
Multicentric	null-type	lymphoma:	C,	D-	negative	reaction	for	both	CD3	and	CD79a	antibodies.
Fig. 3. Immunohistochemical	aspects	of	cutaneous	and	mediastinal	lymphoma.
Cutaneous	T-cell	lymphoma:	A-	positive	reaction	for	CD3	antibody,	B-	negative	reaction	for	CD79a	antibody;
Mediastinal	T-cell	lymphoma:	C-	positive	reaction	for	CD3	antibody,	D-	negative	reaction	for	CD20	antibody.
CORA et al
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Of	all	mediastinal	lymphomas,	60%	(3	cases)	
were	 derived	 from	 B	 lymphocytes,	 while	 the	
remaining	40%	(2	cases)	had	T-cell	origin. These	
results	 are	 not	 similar	 to	 the	 data	 presented	 in	
other	 reports.	 The	 mediastinal	 form	 in	 dogs	 is	
most	commonly	associated	with	the	T	phenotype	
of	tumoral	cells	(Ruslander	et al.,	1996;	Vail	et al.,	
1996).
Figure	 3	 (C	 and	 D)	 shows	 a	 case	 of	 T-type	
mediastinal	 lymphoma.	Thus,	 figure	3C	 indicates	
the	marking	of	cytoplasmic	membrane	for	the	CD3	
antibody,	as	well	as	lack	of	immunlabelling	for	the	
CD20	antibody,	seen	in	figure	3D.
The	 case	 of	 primary	 central	 nervous	 sys	tem	
lymphoma	was	diagnosed	with	B	immunopheno-
type,	 being	 a	 less	 common	 type	 of	 extranodal	
lymphoma	in	dogs.	In	a	study	by	Sisó	et al. (2017)	
were	included	37	dogs	with	primary	(1	case)	and	
secondary	 central	 nervous	 system	 lymphoma.	
About	57%	were	B	cell	lymphomas	and	43%	were	
T	 cell	 lymphomas.	 The	 primary	 central	 nervous	
system	lymphoma	case	had	B	phenotype.
The	 case	 of	 B	 cell	 primary	 central	 nervous	
system	 lymphoma,	 shown	 in	 figure	4	A	and	B,	 is	
characterized	by	the	staining	of	cell	membrane	for	
CD79a	and	CD21	antibodies.
All	 cases	 of	 digestive	 lymphoma	 showed	 T	
phenotype.	 This	 is	 correlated	 with	 other	 recent	
studies	 suggesting	 that	 most	 digestive	 tract	
lymphomas	in	dogs	come	from	T	lymphocytes	and	
often	have	epitheliotropism	(Coyle	and	Steinberg,	
2004;	Ozaki	et al.,	2006).
In	 figure	 4C	 and	 4D	 is	 observed	 a	 case	 of	
digestive	 lymphoma	with	 T	 phenotype,	 showing	
a	positive	reaction	for	the	CD3	antibody,	while	no	
immunolabbelling	 was	 identified	 for	 the	 CD20	
antibody.
Classification	 of	 lymphomas	 according	 to	
immunophenotype	is	of	major	importance	in	their	
therapy	and	prognosis.	Dogs	with	T-cell	lymphoma	
showed	 a	 lower	 rate	 of	 complete	 chemotherapy	
response,	 but	 also	 a	 shorter	 remission	 and	
survival	 time	 than	 dogs	 with	 B-cell	 lymphomas	
(with	 the	 exception	 of	 low-grade	 T-lymphomas)	
(Teske	et al.,	1994;	Ruslander	et al.,	1996;	Vail	et 
al.,	 1996).	 Furthermore,	 T-cell	 lymphomas	 tend	
to	 be	 associated	 with	 hypercalcemia	 (Rosol	 and	
Capen,	1992).
Fig. 4. Immunohistochemical	aspects	of	digestive	and	primary	central	nervous	system	lymphoma.
Primary	central	nervous	system	B-cell	lymphoma:	A,	B-	positive	reaction	for	both	CD79a	and	CD21	antibodies;
Digestive	T-cell	lymphoma:	C-	positive	reaction	for	CD3	antibody;	D-	negative	reaction	for	CD20	antibody.
Immunohistochemical	Characterization	of	Canine	Lymphomas
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CONCLUSION
In	our	paper,	 lymphomas	were	characterized	
depending	 on	 the	 immunophenotype	 into:	 B	
cell	 lymphomas	 (64.1%),	 T	 cell	 lymphomas	
(33.34%)	 and	 null	 type	 lymphomas	 (2.56%).	 B	
cell	 lymphomas	 have	 prevailed	 in	 multicentric,	
mediastinal	 and	 primary	 central	 nervous	
system	 forms,	 while	 most	 of	 cutaneous	 and	
digestive	 lymphomas	 had	 T	 immunophenotype.	
Immunohistochemical	 description	 of	 canine	
lymphomas	 can	 deliver	 some	 major	 details	
concerning	their	behavior	and	malignancy.	
To	 our	 knowledge,	 this	 is	 the	 first	 report	
on	 immunophenotyping	 of	 canine	 lymphomas,	
in	 our	 country.	 Vital	 prognosis	 and	 efficacy	
of	 some	 therapeutic	 protocols	 rely	 on	 the	
immunohistochemical	 features	 of	 canine	
lymphoma,	 thus	 helping	 the	 clinicians	 to	 obtain	
diagnostic	certainty. 
This	research	did	not	receive	any	specific	grant	
from	funding	agencies	 in	 the	public,	 commercial,	
or	not-for-profit	sectors.
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